First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement

CE Activity Release Date: December 13, 2022
CE Activity Expiration Date: December 14, 2023
Time to Complete activity: 1.5 hours

DESCRIPTION

The treatment landscape for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has shifted with the advent of novel targeted agents that are more tolerable than traditional chemoimmunotherapy. The emergence of fixed-duration therapy, which combines two or more agents given within a set timeframe, has shown promise for the treatment of CLL/SLL. However, questions remain regarding optimal combinations and sequencing to best meet the needs of individual patients. Additionally, clinicians must consider the potential of adverse events that can affect patients’ quality of life and outcomes. However, keeping up with the latest evidence and updates to clinical guidelines can be challenging for busy clinicians and their care teams. The 3-part educational initiative First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement is designed to help oncology clinicians address these challenges.

• In episode 1, What You MUST Know About the Emerging Standard of Care for 1L Treatment of CLL and SLL, expert faculty discuss evolving approaches to treating patients with CLL and SLL and how to integrate the new standards into practice.
• In episode 2, Moving Towards Fixed-Duration Therapy in CLL and CLL, expert faculty and special guests discuss the implications of new data regarding fixed-duration therapy, as well as strategies to promote inclusive clinical trial participation.
• The final episode, Help Your Patients Navigate Risk-benefit Assessment, Choose the Best Therapy for Them, and Mitigate TEAEs, focuses on AE management, inclusive decision making, and strategies for patients to monitor and report their symptoms to facilitate timely and effective care.

TARGET AUDIENCE

This CE activity is intended for hematologic oncology clinicians including physicians, fellows, nurse practitioners, nurses, physician associates, and pharmacists who provide care for individuals with CLL and SLL.

EDUCATIONAL OBJECTIVES

After completing this CE activity, the participant should be better able to:

• Incorporate guideline recommendations and real-world evidence supporting the emerging standard of care in practice
• Evaluate emerging data regarding the mechanism of action and long-term safety and efficacy of recommended agents and combinations, including those of fixed duration and mutation-based regimens
• Identify the most common and serious adverse events (AEs) that emerge during treatment with targeted therapies and combination regimens including negative outcomes associated with mutations in black patients
• Plan strategies to mitigate treatment-emergent AEs most troublesome for patients
• Engage patients of all backgrounds and ethnicities in discussion of the risks of AEs relative to treatment outcomes
• Select safe and effective fixed-duration combinations to improve patient care and outcomes
• Recommend appropriate treatment utilizing relevant endpoints, optimal duration, and appropriate sequencing to improve patient outcomes

ACCREDITATION, SUPPORT AND CREDIT

In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION

Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING PROFESSIONAL DEVELOPMENT

Successful completion of this nursing continuing professional development activity will be awarded 1.5 contact hours and 1.5 contact hours in the area of pharmacology.

CONTINUING PHARMACY EDUCATION

Medical Learning Institute, Inc. designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA0007322-0000-22-132-H01-P
Type of Activity: Knowledge

AAPA CREDIT DESIGNATION STATEMENT

Medical Learning Institute, Inc. has been authorize by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until December 14, 2023. PAs should only claim credit commensurate with the extent of their participation.

INTERPROFESSIONAL CONTINUING EDUCATION (IPCE) STATEMENT

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

SUPPORT STATEMENT

Supported by educational grants from Genentech, a member of the Roche Group and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

DISCLOSURE & CONFLICT OF INTEREST POLICY

Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

FACULTY DISCLOSURES

Planner/Presenter
Sanjay K. Juneja, MD
Hematology, Medical Oncology
Chief of Oncology Line
Baton Rouge General Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA

Advisory Board/Consultant: Daiichi Sankyo and Guardant 360
Speakers’ Bureau: AstraZeneca Pharmaceuticals, Daiichi Sankyo, Guardant 360, Merck & Co., Inc. and Tempus
Stock Ownership: Phenomune and xCures
Independent Contractor: xCures

Planner/Presenter
Nicole Lamanna, MD
Associate Attending, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, NY

Advisory Board/Consultant: AbbVie, AstraZeneca, BeiGene, Eli Lilly/Loxo, Genentech, Janssen, and Pharmacyclics
Research Grant: AbbVie, AstraZeneca, BeiGene, Eli Lilly/Loxo, Genentech, Octapharma, Oncternal Therapeutics, MingSight, and TG Therapeutics

Planner/Presenter
Raajit K. Rampal, MD, PhD
Associate Attending Physician
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY

Advisory Board/Consultant for: AbbVie, Blueprint Medicines, Celgene/Bristol Myers Squibb, Constellation, CTI BioPharma, Disc Medicine, Galecto, Incyte, Novartis, Pharmaessentia, Promedior, Servier, Sierra Oncology/GlaxoSmithKline, Stemline, and Sumitomo Dainippon
Research Grant for: Constellation, Incyte, Ryvu, Stemline, Zentalis

Planner/Presenter
Christina Russomanno, MSN, RN, NP-C
Medical Oncology, Nurse Practitioner
Columbia University
Herbert Irving Comprehensive Cancer Center
New York, NY

Advisory Board/Consultant for: AbbVie

Planner/Presenter
Erika Pomares, LMSW
Senior Manager, Patient & Community Outreach
The Leukemia & Lymphoma Society
Rye Brook, NY

Erika Pomares, LMSW, has no relevant financial relationship with ineligible companies to disclose for this educational activity.

Patient/Planner/Presenter
Greg Simon

Advisory Board/Consultant for: Day One Therapeutics, Vaxart, WinSanTor
Stock Ownership: Day One Therapeutics

All of the relevant financial relationships of individuals for this activity have been mitigated.

PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit.

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org

For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

ABOUT THIS ACTIVITY

Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters

Copyright © 2022 Medical Learning Institute, Inc | All Rights Reserved